Can a High Reloading Dose of Atorvastatin Prior to Percutaneous Coronary Intervention Reduce Periprocedural Myocardial Infarction?

Abstract

Background:

Periprocedural myocardial infarction (MI) is a common complication following percutaneous coronary intervention (PCI) and statins have been shown to reduce MI in statin-naïve patients. We aimed to identify whether a high reloading dose of atorvastatin can prevent MI following PCI in patients who were already being treated with statins.

Material and methods:

In this triple-blind controlled randomized clinical trial, 190 candidates for elective PCI, who were already using statins and/or other lipid lowering agents such as fibrates, were randomly assigned to two equal groups to receive either atorvastatin (80 mg) or placebo within 24 hours before the procedure. Serum levels of creatinine kinase myocardial isoenzyme (CK-MB), cardiac troponin I (cTNI) and high-sensitive C-reactive protein (hs-CRP) were measured at baseline and then 6 and 12 hours following PCI. Post-procedural MI was defined as troponin elevation >5-fold in patients with normal baseline or >20% in those with elevated baseline measurements with or without chest pain or ST segment or T wave abnormalities.

Results:

Frequency of MI in the atorvastatin group was 3 (3.1%) vs. 10 (10.5%) in the placebo group (p = 0.04). The CK-MB rise within 6 hours following PCI was 0.6 ± 0.3 mg/dl in the intervention group versus 3.0 ± 1.6 mg/dl in the placebo group. Also, the levels of cTNI within 6 and 12 hours in the intervention group was significantly lower than the placebo group (p = 0.01 and 0.008, respectively). hs-CRP was significantly lower in the intervention group after 12 hours (p = 0.004).

Conclusion:

Administration of a high reloading dose of atorvastatin within 24 hours before PCI could significantly reduce the frequency of periprocedural MI.

Clinical trial registration code:

IRCT201205209768N1.

Keywords::

• Atorvastatin
• Cardiac troponin I
• Creatine kinase MB
• Myocardial infarction
• Percutaneous coronary intervention

Transparency

Declaration of funding

This study was supported and financed by Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Latifeh Nafasi^a

Reza Rahmani^a

Akbar Shafiee^b

Arsalan Salari^a

Alireza Abdollahi^a

Alipasha Meysamie^c

Declaration of financial/other relationships

L.N., R.R., A.Sh., A.Sa., A.A., and A.M. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewers may have received honoraria for their review work. The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.

Acknowledgments

This work was the thesis of Dr. Latifeh Nafasi for obtaining a cardiology specialty degree. The authors sincerely thank the laboratory staff of Imam Khomeini Hospital.